Flucytosine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Flucytosine}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ANCOBON (FLUCYTOSINE) CAPSULE [VALEANT PHARMACEU...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Adverse Reactions== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ANCOBON (FLUCYTOSINE) CAPSULE [VALEANT PHARMACEUTICALS NORTH AMERICA LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea0df00-a88c-4a16-abcf-750f3ff2004e | publisher = | date = | accessdate = }}</ref> | The adverse reactions which have occurred during treatment with Ancobon are grouped according to organ system affected. | ||
*:'''Cardiovascular''': [[Cardiac arrest]], myocardial toxicity, ventricular dysfunction. | |||
*:'''Respiratory''': Respiratory arrest, chest pain, dyspnea. | |||
*:'''Dermatologic''': Rash, [[pruritus]], [[urticaria]], [[photosensitivity]]. | |||
*:'''Gastrointestinal''': Nausea, emesis, abdominal pain, diarrhea, anorexia, dry mouth, duodenal ulcer, gastrointestinal hemorrhage, acute hepatic injury including hepatic necrosis with possible fatal outcome in debilitated patients, hepatic dysfunction, jaundice, ulcerative colitis, enterocolitis, bilirubin elevation, increased hepatic enzymes. | |||
*:'''Genitourinary''': Azotemia, creatinine and BUN elevation, crystalluria, renal failure. | |||
*:'''Hematologic''': [[Anemia]], [[agranulocytosis]], [[aplastic anemia]], [[eosinophilia]], [[leukopenia]], [[pancytopenia]], [[thrombocytopenia]], and fatal cases of bone marrow aplasia. | |||
*:'''Neurologic''': Ataxia, hearing loss, headache, paresthesia, [[parkinsonism]], peripheral neuropathy, pyrexia, vertigo, sedation, convulsions. | |||
*:'''Psychiatric''': Confusion, hallucinations, [[psychosis]]. | |||
*:'''Miscellaneous''': Fatigue, hypoglycemia, hypokalemia, weakness, allergic reactions, [[Lyell’s syndrome]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ANCOBON (FLUCYTOSINE) CAPSULE [VALEANT PHARMACEUTICALS NORTH AMERICA LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea0df00-a88c-4a16-abcf-750f3ff2004e | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 19:34, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The adverse reactions which have occurred during treatment with Ancobon are grouped according to organ system affected.
- Cardiovascular: Cardiac arrest, myocardial toxicity, ventricular dysfunction.
- Respiratory: Respiratory arrest, chest pain, dyspnea.
- Dermatologic: Rash, pruritus, urticaria, photosensitivity.
- Gastrointestinal: Nausea, emesis, abdominal pain, diarrhea, anorexia, dry mouth, duodenal ulcer, gastrointestinal hemorrhage, acute hepatic injury including hepatic necrosis with possible fatal outcome in debilitated patients, hepatic dysfunction, jaundice, ulcerative colitis, enterocolitis, bilirubin elevation, increased hepatic enzymes.
- Genitourinary: Azotemia, creatinine and BUN elevation, crystalluria, renal failure.
- Hematologic: Anemia, agranulocytosis, aplastic anemia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia, and fatal cases of bone marrow aplasia.
- Neurologic: Ataxia, hearing loss, headache, paresthesia, parkinsonism, peripheral neuropathy, pyrexia, vertigo, sedation, convulsions.
- Psychiatric: Confusion, hallucinations, psychosis.
- Miscellaneous: Fatigue, hypoglycemia, hypokalemia, weakness, allergic reactions, Lyell’s syndrome.[1]
References
Adapted from the FDA Package Insert.